



Agenda

RIFT VALLEY FEVER (RVF) VACCINE DEVELOPMENT, PROGRESS AND CONSTRAINTS

INTERNATIONAL WORKSHOP



GF-TADs

GLOBAL FRAMEWORK FOR THE
PROGRESSIVE CONTROL OF
TRANSBOUNDARY ANIMAL DISEASES

Wednesday, 19 January 2011

09.00 Registration at the entrance of Mexico Room (building D)

Chair morning session: Stephane DeLaRocque

09.45 Welcome on behalf of FAO

Juan Lubroth

Welcome on behalf of OIE

Francois Diaz

Introduction round

Goals of the meeting and logistical information

Peter de Leeuw

10.30 **Coffee break**

11.00 "Set the scene" introductions on RVF

IAEA/FAO/WHO

11.45 RVF in South Africa: the evolution and outbreaks

Truuske Gerdes

12.15 Experience with RVF in goats in Egypt*

Samia Ahmed Kamal

12.30 General discussion morning session

12.45 **Lunch**

Chair afternoon session: James Zingeser

14.00 Strategy for the prevention and control of RVF and expectations from the use of vaccines

*Stephane DeLaRocque,
Pierre Formenty*

14.30 OIE-relevant activities and standards related to Rift Valley Fever

Francois Diaz

15.00 RVF and the European Commission*

Ramunas Freigofas

15.30 **Coffee break**

16.00 RVF and the US Government*

William Wilson

16.30 View of NGO*

Baptiste Dungo

17.00 View of the industry*

Barbara Freischem

17.30 General discussion afternoon session

18.30 **Cocktail in the Aventino Room**

* Preliminary title

Thursday, 20 January 2011

Chair morning second day: Rob Moormann

08.30 Development of live attenuated RVF virus vaccines for animal use *George Bettinger*

09.00 Update on Clone 13 vaccination trials *Michelle Bouloy*

09.30 RVF vaccine and DIVA assay efforts *Stuart Nichol*

10.00 Capripoxvirus-vectored recombinant RVF vaccines *David Wallace*

10.30 **Coffee break and group photo**

11.00 Capripox constructs* *Catherine Cêtre-Sossah*

11.30 Protection of sheep against RVF virus with a recombinant sheep pox virus vaccine *Reuben Soi*

12.00 Discussion morning session

12.30 **Lunch**

Chair afternoon second day: Stuart Nichol

14.00 DNA and viral-vectored vaccines for RVF: preclinical development and potential for clinical testing *Alejandro Brun and Sarah Gilbert*

14.30 RVF immunity provided by a paramyxovirus vaccine vector *Jeroen Kortekaas*

15.00 Protective efficacy of several experimental and commercial vaccines not only against a needle challenge, but also an aerosolized RVF virus challenge in a mouse, sheep, and non-human primate model *Ted Ross*

15.30 **Coffee break**

16.00 Transcriptionally active VLPs of RVF virus *Friedeman Weber*

16.30 A virus-like particle based vaccine technology targeting RVF virus *Ramon Flick*

17.00 Discussion afternoon session

* *Preliminary title*

Friday, 21 January 2011

Chair of the last session: Pierre Formenty

08.30 RVF primate model* *Darci Smith*

09.00 Current Status of RVF vaccine development and the way ahead:
opportunities and constraints *Rob Moormann*

09.30 General discussion including the role of the international organizations

10.00 **Coffee break**

10.30 Continuation of the general discussion

11.00 Approval of Recommendations

12.00 Closure of the meeting

* *Preliminary title*